List of Vendor Companies in Denmark - 26

We help accelerate the World's quest for sustainable food and materials The world needs new solutions to tackle the mounting sustainability challenges. Biotech offers an extraordinary potential to replace and improve many foods and materials with attractive sustainable bio-based solutions*. With the advances in technology, insight and data, the discovery of new molecules has only just begun. However, far too few promising molecule innovations have been successfully commercialized and made a true sustainable impact on the World. 21st.BIO helps you accelerate by building a competitive manufacturing foundation for your innovation - allowing you to focus on succeeding in the market and your next discovery. We partner with you on your journey to the market through: 1) Assessment of the technical potential in delivering your innovation – the expression system, the strain base, yield potential, investments required and the best way forward 2) Access to and optimization of high-performance strain platforms and production media across multiple expression systems 3) Building your scale up process and provide volumes for testing your innovations in the market 4) Providing a high quality, proven low investment way for you to manufacture in very large scale – your "fermentation cloud solution"

AFYX is an innovative niche developer of pharmaceuticals aiming at securing better treatments of diseases with unmet medical needs, such as cancer, women's health and severe pain. Our Research & Development, as well as reformulation of pharmaceuticals based on our patented technologies, helps to improve challenging health issues. We believe our focus will change people's lives. Dr. Claus J. Møller-San Pedro is the company CEO. Dr. Møller co-founded and secured successful IPOs of 3 companies in the BioPharma Industry (OXiGENE, Inc; Genmab A/S and Y-mAbs Therapeutics, Inc.) OUR HISTORY is based on the merger of three great and innovative companies bringing significant synergies together – the companies were: INPHENA A/S, a company that already has commercial activities in several countries and develop repurposed existing pharmaceutical substances for new indications. LIONHEART, a company focused on treatment of chronic and intermittent cluster headache. A dramatic a severely debilitating disease with limited treatment options available – We have patent protection for the use of ketamine as nasal administration in this indication. AFYX THERAPEUTICS A/S, a company based on development of a proprietary patented patch technology that sticks to wet surfaces and delivers pharmaceutical products locally where the patch is applied. Our two first projects focus on inflammatory diseases in the oral cavity – oral lichen planus – also a significant unmet medical need and precancerous stages of head and neck cancer in the mouth where we aim to develop a chemotherapy containing patch.

Albumedix is an England-based biotechnology company that manufactures and markets albumins for vaccine stabilization, cell and gene therapy applications.

Innovations that make a difference Ever since 1937, Ambu has been rethinking medical solutions to save lives and improve patient care. Millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia, and patient monitoring solutions. In the past, we provided a way to maintain or restore breathing in any environment with the world's first self-inflating resuscitator, the Ambu® Bag™, which is still in use today. More recently, we responded to a need for an endoscopy solution that is always available. The result? Ambu® aScope™, the world's first sterile, single-use flexible endoscope. Today, we continue to collaborate with leading medical experts to deliver innovations that make a real difference to healthcare professionals and their patients. At our headquarters in Copenhagen, Denmark, and around the world in Europe, North America and the Asia Pacific, 4,500+ team members keep Ambu moving forward. Ambu – Forever Forward For more information, please visit www.ambu.com

Aquaporin is an innovative water technology company with operations in Denmark (HQ), Singapore, Turkey, the United States, and China. We are committed to rethinking water filtration with biotechnology to solve global water challenges. By combining three disciplines from the world of natural sciences: biology, chemistry, and physics, we have created the unique, nature-inspired Aquaporin Inside® technology which we embed into all our membranes and solutions. Our technology is based on Nobel Prize-winning research and is used to clean and reuse water in industries, in our homes, and even by NASA in space. We work with customers and partners around the globe to responsibly treat industrial wastewater, concentrate food and beverage products in a natural way, and enhance drinking water quality and accessibility.

Eurofins Genomics was founded in 1990 and is part of the Eurofins Scientific Group, a Life Science Company with laboratories in 61 countries and 61,000 employees. We are an international provider of genomic services around the core business lines next generation sequencing, genotyping, gene expression, custom DNA sequencing, oligonucleotides, siRNA and gene synthesis. Our services are tailored for pharma, diagnostics, agriculture, food, biotechnology and research applications worldwide. Imprint: https://www.eurofinsgenomics.eu/imprint/ Privacy Note: https://www.eurofinsgenomics.eu/privacy/

Axlab A/S is a Danish-owned company that since 1993 has supplied advanced equipment to pathology departments at hospitals and laboratories. Today, we deliver solutions throughout Europe and the United States. We are headquartered in Vedbæk, near Copenhagen and have a subsidiary in Sweden. The ability to understand the everyday life of the individual bioanalyst and pathologist is absolutely essential for Axlab. We have our roots in the world of the laboratory and visit the pathology departments of the hospitals as often as possible to experience the challenges of everyday life up close. And it is with this valuable knowledge as inspiration that we deliver the advanced technological solutions that are not only crucial for the laboratory’s efficiency but also ensure an optimal working environment and the highest possible quality in the analysis work. For the benefit of both staff and patients.

BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem. The Company’s flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury (AKI), a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, clinicians can identify patients potentially at risk of AKI more rapidly than is possible with the current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide. BioPorto has facilities in Copenhagen, Denmark, and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit www.bioporto.com. To learn more about our products and their availability in your country, please visit https://bioporto.com/products/. Posts are not intended for a U.S. audience. If you are from the United States, you are encouraged to visit https://www.linkedin.com/company/bioporto-diagnostics-inc-us/ Social Media Community Guidelines: https://bioporto.com/social-media/

Cellari enables doctors and non-specialists to take full advantage of recent developments in artificial intelligence. Cellari aims to provide the most precise "active learning model" for biological image segmentation combined with an intuitive and easy-to-use user interface for carrying out complex image related tasks and analytics. An automated statistical testing service ensures statistical validity of clinical and research related results along with unparalleled review and methodology transparency functionalities. Cellari is a proud part of the InnoFounder – Graduate incubator for Cohort 5 of September 2019.

We help organisations and people with important missions to develop and aspire. That's it. International Organisational Development & Organisational Assessment. Most endorsed for... 100+ Organizational Development 100+ Talent Management 98 Human Resources 71 Performance Management 65 Change Management 65 Employee Relations 54 Personnel Management 36 Management 34 Management Consulting

Evosep develops new solutions to make clinical proteomics 100 times more robust and 10 times faster. We are targeting the growing need for throughput with robust solutions for clinical and large-scale proteomics, and we have a very ambitious business plan to bring the community closer to the clinic. We are basing our design on years of experience with nano-UHPLC R&D and application support, critically rethinking the necessary system architectures for successful sample separation before mass spectrometric analysis.

ExpreS2ion Biotechnologies is a clinical-stage DK based biotech company specialised in the development of new vaccines and immunotherapy products. The company has a discovery platform built around a proprietary recombinant expression system, ExpreS2 TM, developed especially for fast and efficient development and production of complex proteins required for innovative new vaccines, immunotherapy and diagnostics. The system also includes functionally modified glycosylation variants. For the clinical Phase III-stage COVID-19 vaccine, ABNCoV2, the Company employs a novel plug-&-play capsid virus-like particle (cVLP) platform, that offers competitive advantages in terms of long-term efficacy, safety, stability, and costing. The cVLP and ExpreS2 TM platforms are also basis for a proprietary HER2-cVLP breast cancer vaccine, ES2B-C001, which has proven preclinical proof of concept and is on path towards clinical investigations. The development pipeline also has projects based on the ExpreS2 platform alone, including multiple clinical-stage malaria vaccine projects sponsored by academic partners, as well as novel preclinical-stage influenza and CMV vaccines, the latter in a research collaboration with Evaxion Biotech. Since founded in 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with a high number of leading research institutions, biotech and pharma companies, demonstrating superior efficiency and success rates. The cVLP platform resides in its 34%-owned associated company AdaptVac that was founded in 2017. ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary and operational unit of ExpreS2ion Biotech Holding AB, listed on Nasdaq First North Growth Market, Stockholm (Ticker: EXPRS2).

Fida Biosystems (Fidabio) offers a new proprietary technology developed for quantification and characterization of proteins and nanoparticles from 0.5 to 1,000 nm Dh, incl. antibodies, liposomes, exosomes, membrane embedded proteins et al. Based on accurate, in-solution, absolute measurements of hydrodynamic radius, the technology provides precise information about Kd, concentration, size, stoichiometry, conformational changes, oligomeric state, immunogenicity, multiple bindings etc. It is characterised by being fast (minutes), requiring very small sample amounts (ul-nl), and being exceptionally tolerant to the sample matrix, incl. plasma, serum, cell lysate, fermentation media etc. Contrary to most other procedures, the methodology is based on binding in homogenous solution; complications related to non-specific surface adsorption and challenging assay development are therefore avoided. I.e. the unique features of the FIDA technology enable characterisation and quantification in native (biorelevant) environments and in-built assay quality control and automation.

Forward Pharma A/S is a biopharmaceutical company that developed a proprietary formulation of DMF for the treatment of inflammatory and neurological indications.

Immudex is a pioneering life science company spearheading the global adoption of precision immune monitoring. Since 2009, Immudex has been striving to provide researchers worldwide with reliable tools to monitor the cellular immune response accurately. Our goal is to utilize the complex actions and interactions of the immune system to help researchers better understand the causes, accelerate the diagnosis, and more accurately predict the prognosis of diseases. To that end, Immudex markets prime Dextramer® and dCODE® (DNA-barcoded) MHC multimer technologies that grant researchers and clinicians detailed insights into disease-specific immunity resolved to antigen-specific cell populations and single cells. Additionally, Immudex is mandated by the CIC and CIMT to coordinate yearly evaluations of T-cell immune monitoring proficiency and drive the generation of high-quality data that advance immunotherapies. Research, development, and commercial activities are headquartered in Copenhagen, Denmark, with operations in North America out of Fairfax, Virginia. Find out more at www.immudex.com.

Established in 2016, Kaffe Bueno is the first company to ever fully breakdown and valorise spent coffee grounds into active and functional ingredients for personal care, advanced materials, animal and human nutrition. Through cutting-edge technology and patented applications of the unique coffee molecules, Kaffe Bueno is the pioneer and leader of the coffee upcycling movement. Our mission is to unlock coffee's health potential where harmful emissions are minimised and coffee's by-product usability is maximised. By extending coffee's economical life, we will be able to give back to the people we owe its existence; farmers. Our vision is to transform the way people perceive coffee; from looking at it as a tool to make it until the end of the day, to look at it as a magical bean with the potential of improving human health by using what lies inside it.

MethylDetect ApS is a supplier of high-quality, ready-to-use DNA methylation detection kits, located in Aarhus and Aalborg, Denmark. Our innovative EpiMelt kits are based on the Methylation-Sensitive High-Resolution Melting technology (MS-HRM), enabling highly sensitive, cost-effective, and user-friendly detection of DNA methylation changes in biological material. We have a broad catalogue, and our products are available worldwide, with distributors in key locations across the globe. At MethylDetect, we are committed to making high-quality methylation detection easy and accessible. While being affordable, the EpiMelt DNA methylation detection kits rapidly and reliably detect changes in methylation patterns, and can therefore provide key insights and actionable results through all steps of Life Science research and drug development, in both small scale and high-throughput settings. Ultimately, it is our goal here at MethylDetect to provide fast, sensitive, and reliable solutions to the field of research and development.

PentaBase is a knowledge-based Danish pharmacogenomics company founded and managed by researchers and located in the heart of Denmark. We specialise in custom oligonucleotide production and the development of in vitro diagnostic assays for real-time PCR with a special focus on the detection of somatic mutations in cancer and COVID-19. For more than 10 years, PentaBase has created products for researchers and medical professionals exploring new treatments and helping patients worldwide. Our products are given unique abilities in the analysis and manipulation of genetic material with our proprietary technology, INAs® (Intercalating Nucleic Acids). Medical professionals and researchers use these features to help treat diseases and acquire new knowledge. We believe in open-platform designs and strive to make our products compatible with basic instruments used in molecular biology facilities worldwide. For more information, please contact us at: Tel: +45 3696 9496 Mail: info@pentabase.com https://www.pentabase.com/

PolyPeptide Group AG with its consolidated subsidiaries (“PolyPeptide”) is a focused Contract Development & Manufacturing Organization (CDMO) which specializes in the development and manufacturing of synthetic peptides and oligonucleotides used as active pharmaceutical ingredients (API) or intermediates in therapeutic products. It also produces a range of generic peptides and peptides used in cosmetics. The Group mainly serves pharmaceutical and biotech companies. By supporting its customers, PolyPeptide contributes to the health of millions of patients across the world. PolyPeptide provides its offering from pre-clinical through to commercial stages. Its active custom projects pipeline reflects the opportunities from novel drug therapies in development to fight both widespread and rare diseases. Established in 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange. Find out more about our current vacancies at: https://polypeptide.teamtailor.com/

Reshape Biotech is building the next generation of lab automation robots. Our customers are biotech companies tackling the world’s biggest problems - be it alternative protein development or sustainable agriculture. Reshape Biotech is the scaling factor for these companies, as we let researchers collaborate globally on experiments and increase their throughput >500x. The team is highly multi-disciplinary, employing everything from PhD’s in biology to hardware and software engineers. We work closely together, and you will be exposed to a truly vertical team. We’re a fast growing startup with an incredibly ambitious team, dead-set on reinventing a 100 year old industry and becoming the standard infrastructure that the world of biotech relies on. Our customers already include global leaders in food, agriculture and biologicals. We’re backed by top tier investors from Y Combinator, CEOs from the industry and some of the biggest names you can find. At Reshape Biotech, you have the potential to influence how biotech research is done in the next 100 years.

Tailwind Biotech is a biotech company offering synthetic DNA design services for improved strain development. We use proprietary Artificial Intelligence to help bioproduction-based companies worldwide achieve more effective and more efficient genetic engineering processes. Our technology designs optimized DNA sequences that help to maximize biological manufacturing yields while reducing development costs. We believe that by leveraging the powerful mix of Artificial Intelligence and Synthetic Biology, we can accelerate advancements in healthcare, agriculture, sustainable energy and beyond.

Join Unibio's journey in solving the World's protein scarcity challenge here. One of the great challenges of humankind is how we can feed a fast-growing global population entitled to safe, healthy and affordable nutrition. In this endeavor, a robust supply of protein is key, a nutritional cornerstone and a necessary building block of all life and essential to the growth of cells and tissue repair. We believe the solution lies in Unibio's high potential and mass-produced microbial protein; a tested, safe, eco-friendly, ethical technology approved by the EU capable of industrialising protein production for animal feed. Unibio is committed to a journey towards a world without protein scarcity.

VenomAid Diagnostics is a young, impact-oriented medtech start-up developing affordable, easy-to-use, and robust diagnostics enabling best-in-class snakebite management worldwide, ultimately reducing the global burden of snakebite. Snakebite is a global problem affecting millions of people worldwide, most severely in low- and middle-income countries. The only effective treatment, specific antivenom, is scarcely available and can only be given if the perpetrating snake is known.

We are a leading provider of AI-driven precision pathology software for research and diagnostics. In research, we are a technology leader providing tools that help scientists, pathologists, and image analysis experts produce accurate data for all types of tissue-based research. In diagnostics, we are a leader within clinical applications, with no less than eight diagnostic algorithms cleared under IVDR for EU customers. These applications provide diagnostic decision support and and can be easily activated and integrated into existing lab workflows. Founded in 2002, we are privately owned and operate internationally with over 750 customer accounts in more than 40 countries. Our company’s headquarters are located in Denmark’s Medicon Valley, with offices in Sweden, the UK, Germany, the Netherlands, and the United States, and local representation in France and China.

Demant is a world-leading hearing healthcare and technology group built on a heritage of care, health and innovation since 1904. The Group offers solutions and services to help people connect and communicate with the world around them. For more than a century, the Demant Group has played a vital part in developing innovative technologies and gathering know-how to help improve people's hearing and health. In every aspect, from providing hearing care to delivering hearing aids, hearing implants and diagnostic equipment and services to hearing care professionals and users all over the world, Demant is active and engaged. And with the Group's many years of experience with audio and hearing technology, Demant has evolved into a growing business within premium audio and video solutions for enterprises and gaming. The Demant Group operates in a global market with subsidiaries in more than 30 countries, employs more than 20,000 employees and generates an annual revenue of more than DKK 19 billion. Our products are sold in more than 130 countries where we create life-changing differences through hearing health. Listed on Nasdaq Copenhagen stock exchange, Demant is the parent company behind world-renowned and commercially successful brands as Oticon, Bernafon, Sonic, Philips Hearing Solutions, Audika, Oticon Medical, MAICO, Interacoustics, Amplivox, Grason-Stadler, MedRx, Audioscan and EPOS. The William Demant Foundation holds the majority of shares in Demant A/S, which is listed on Nasdaq Copenhagen and among the 25 most traded stocks. If you want to know how we process your personal data on social media platforms, visit this site: https://www.demant.com/privacy-notice#some

Zerion is a pharmaceutical company transforming the pharmaceutical landscape for formulation of poorly soluble drugs that are currently not reaching their therapeutic potential. Through the use of our proprietary formulation platform, we aim to develop new treatment options for patients across all small molecule therapy areas. We are focused on improving existing drug products by building an internal pipeline, while partnering with originators to enable their early stage drug molecules, striving to improve the lives of patients around the world.